18F-rhPSMA-7.3 PET/CT在前列腺癌生化复发中的检测效能与管理影响
该回顾性研究纳入242例根治性前列腺切除术后生化复发、尚未接受挽救治疗的患者,评估18F-rhPSMA-7.3 PET/CT的病灶检出率及对临床管理的影响。总检出率为72.7%,随PSA升高检出率增加,模拟肿瘤委员会认为63.2%的患者治疗管理可能发生改变。
要点
- 18F-rhPSMA-7.3 PET/CT总病灶检出率为72.7%(176/242)。
- PSA 0.2–<0.5 ng/mL亚组检出率为61.8%,其中8.8%发现骨病灶。
- 模拟肿瘤委员会认为63.2%患者治疗管理可能改变,22.3%为重大改变。
核心结论
- 18F-rhPSMA-7.3 PET/CT在根治性前列腺切除术后生化复发且尚未接受挽救治疗的患者中具有高检测效能,并使近三分之二患者的治疗方案可能发生改变。
研究设计与样本
- 回顾性研究,从机构数据库筛选242例根治性前列腺切除术后生化复发、未接受挽救治疗的患者,中位PSA为0.60 ng/mL(范围0.2–60.8 ng/mL),由经验丰富的核医学医师重新判读图像,并按PSA分层分析检出率及模拟肿瘤委员会评估治疗管理变化。
主要发现
- 176/242(72.7%)患者出现PSMA配体阳性发现。
- PSA 0.2–<0.5、0.5–<1、1–<2和≥2 ng/mL亚组的检出率分别为61.8%(63/102)、67.9%(38/56)、81.1%(30/37)和95.7%(45/47)。
- 局部复发、盆腔淋巴结转移、腹膜后淋巴结转移、膈上淋巴结、骨转移和内脏转移分别见于48.8%(n=118)、28.9%(n=70)、6.6%(n=16)、1.2%(n=3)、13.2%(n=32)和1.2%(n=3)的患者。
- PSA<0.5 ng/mL的患者中,8.8%(9/102)发现骨病灶。
- 模拟肿瘤委员会结果显示,153/242(63.2%)患者治疗管理发生改变,其中54例(22.3%)为重大改变、99例(40.9%)为轻微改变;64例(26.4%)未引发治疗改变。
临床怎么用
- 对于根治性前列腺切除术后生化复发、尚未接受挽救治疗的患者,18F-rhPSMA-7.3 PET/CT可提供高检出率并可能影响治疗决策。
局限性
- 本研究为回顾性设计,数据来自单机构数据库。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Radiohybrid prostate-specific membrane antigen (rhPSMA) ligands are a new class of 18F-labeled PSMA-targeting agents. 18F-rhPSMA-7.3 is a lead compound that is currently under investigation in 2 multicenter phase III trials for PET imaging. Here, we report the first retrospective data on its detection efficacy and potential impact on clinical management in a homogeneous cohort of patients with biochemical recurrence after radical prostatectomy and before any salvage therapy. Methods: In total, 242 patients (median prostate-specific antigen [PSA], 0.60 ng/mL; range, 0.2-60.8 ng/mL) who underwent 18F-rhPSMA-7.3 PET/CT were retrospectively selected from the institution's database. Images were reread by an experienced nuclear medicine physician. Lesion detection rates were stratified by PSA. Further, potential management before and after PET was assessed by an interdisciplinary simulated tumor board and categorized (major vs. minor vs. no therapeutic change). The distribution of management change identified in each PSA subgroup was determined. Results: In total, 176 of 242 (72.7%) patients showed PSMA-ligand-positive findings. 18F-rhPSMA-7.3 detection rates were 61.8% (63/102), 67.9% (38/56), 81.1% (30/37), and 95.7% (45/47) for PSA levels of 0.2 to less than 0.5 ng/mL, 0.5 to less than 1 ng/mL, 1 to less than 2 ng/mL, and at least 2 ng/mL, respectively. 18F-rhPSMA-7.3 PET/CT revealed local recurrence, pelvic lymph node metastases, retroperitoneal lymph nodes metastases, supradiaphragmatic lymph nodes, bone metastases, and visceral metastases in 48.8% (n = 118), 28.9% (n = 70), 6.6% (n = 16), 1.2% (n = 3), 13.2% (n = 32), and 1.2% (n = 3) of patients, respectively. Notably, bone lesions were identified in 8.8% of patients (9/102) with a PSA of less than 0.5 ng/mL. Results from the tumor board indicated a change in therapeutic management in 153 of 242 patients (63.2%), with 54 (22.3%) considered major and 99 (40.9%) minor. 18F-rhPSMA-7.3 PET/CT did not prompt any therapeutic changes in 64 patients (26.4%). Conclusion: 18F-rhPSMA-7.3 PET offered high detection efficacy in patients with biochemical recurrence after radical prostatectomy and before potential salvage therapy and resulted in a potential change in treatment plan in nearly two thirds of patients.
引用
- Rauscher I, Karimzadeh A, Schiller K, et al. Detection Efficacy of 18F-rhPSMA-7.3 PET/CT and Impact on Management in Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy and Before Potential Salvage Treatment. J Nucl Med. 2021. PMID: 33712531. doi:10.2967/jnumed.120.260091
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。